Group 1 - The event successfully integrated traditional Chinese medicine health concepts with community sports, providing an innovative model for community health culture construction [1][5] - The series of community table tennis events took place in seven major cities, including Zhengzhou, Shenyang, Beijing, Shijiazhuang, Weihai, Linyi, and Guangzhou, with a total of 10 events held [1] - The unique approach of using table tennis as a medium for brand interaction allowed the brand's message to become a tangible experience for participants [1][3] Group 2 - The project translated traditional Chinese medicine concepts into modern language, making them accessible and relatable to the public, thus fostering community connections through the sport [3][5] - The successful execution of the events demonstrated the brand's strong localization capabilities and its ability to resonate with diverse cultural backgrounds across different regions [3] - The initiative represents a shift for traditional brands like Beijing Tongrentang, positioning them as advocates for the creative transformation and innovative development of traditional culture [5][7] Group 3 - The community health journey, while concluding, has planted seeds of health awareness and vitality that will resonate on a broader social level [7] - The brand aims to continue its commitment to health and cultural confidence by delivering its health promises to households through diverse innovative formats [7]

Core Viewpoint - Tongrentang (600085) has received approval from the Canadian Ministry of Health for the product license of its product, Shenling Baizhu Powder, which indicates a significant step in its international expansion efforts [1] Group 1: Product Development and Approval - The product Shenling Baizhu Powder has been successfully registered with a cumulative R&D investment of approximately 2.29 million yuan (unaudited) [1] - The primary indications for Shenling Baizhu Powder include alleviating symptoms such as spleen and stomach weakness, reduced appetite, diarrhea, shortness of breath, cough, and fatigue [1] Group 2: Market Entry Challenges - Despite obtaining the product license, the company must still complete several administrative approval processes, including certification of the Canadian production quality system, before it can sell the product in Canada, indicating a level of uncertainty [1]

Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

Core Viewpoint - Tongrentang has received approval from the Canadian Ministry of Health for its product, Shenling Baizhu San, which is now registered in Canada for specific health indications [1] Company Summary - Tongrentang's subsidiary, Beijing Tongrentang Co., Ltd., has been granted a Class III Product License by the Canadian Ministry of Health [1] - The product Shenling Baizhu San is indicated for alleviating symptoms related to spleen and stomach weakness, including reduced appetite, loose stools, shortness of breath, cough, and fatigue [1]

Core Viewpoint - Tong Ren Tang (600085.SH) has received approval from the Canadian Ministry of Health for its product license, allowing its product Shen Ling Bai Zhu San to be registered in Canada [1] Group 1 - The announcement highlights that the Beijing Tong Ren Tang Pharmaceutical Factory, a branch of Tong Ren Tang, has successfully obtained a Class III product license [1] - The approval signifies an important step for the company in expanding its market presence in Canada [1]

Core Viewpoint - Tong Ren Tang (600085.SH) has received approval from the Canadian Ministry of Health for a Class III Product License, allowing its product Shen Ling Bai Zhu San to be registered in Canada [1] Group 1 - The announcement highlights the successful registration of Shen Ling Bai Zhu San, indicating the company's expansion into the Canadian market [1] - This approval reflects the company's commitment to international growth and the increasing recognition of traditional Chinese medicine products [1]

北京同仁堂股份有限公司（以下简称公司）分支机构北京同仁堂股份有限公 司同仁堂制药厂（以下简称同仁堂制药厂）收到加拿大卫生部核准签发的《产品 许可证（三类）》，同仁堂制药厂产品参苓白术散获得加拿大产品注册。公司现将 有关情况公告如下： 一、 产品注册许可基本情况 产品名称：参苓白术散 产品剂型：散剂 品种批准文号：80143529 持证商名称：北京同仁堂股份有限公司同仁堂制药厂 证券代码：600085 证券简称：同仁堂 公告编号：2025-040 北京同仁堂股份有限公司 关于获得加拿大产品许可证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 在境外销售产品容易受到境外政策环境变化、市场推广、客户认可、市场竞 争等多种因素影响，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 北京同仁堂股份有限公司董事会 2025 年 12 月 9 日 持证商地址：北京市大兴区中关村科技园区大兴生物医药产业基地天贵大街 33 号 产品适应症：基于传统中医药理论的药物/产品/制剂；用于缓解脾胃虚弱， 症见食少便溏，并能缓解气短，咳嗽，肢倦 ...

Core Viewpoint - Tong Ren Tang (600085.SH) has received approval from Health Canada for its product Shen Ling Bai Zhu San, marking a significant step in its international expansion efforts [1][2] Group 1: Product Approval - The product Shen Ling Bai Zhu San has been granted a Class III product license by Health Canada, indicating its compliance with Canadian regulations [1] - The product is based on traditional Chinese medicine principles and is indicated for alleviating symptoms related to spleen and stomach weakness, such as reduced appetite and loose stools, as well as for relieving shortness of breath, cough, and fatigue [1] Group 2: Research and Development Investment - As of the date of the announcement, the cumulative investment in the research and development of the product amounts to approximately 2.29 million yuan, which is unaudited [2]

Core Viewpoint - Tong Ren Tang (600085) has received approval from the Canadian Ministry of Health for its product, Shen Ling Bai Zhu San, which is now registered in Canada for use in traditional Chinese medicine [1] Group 1: Company Developments - Tong Ren Tang's subsidiary, Tong Ren Tang Pharmaceutical Factory, has been granted a Class III Product License by the Canadian Ministry of Health [1] - The product Shen Ling Bai Zhu San is indicated for alleviating symptoms related to spleen and stomach weakness, including reduced appetite and loose stools, as well as for relieving shortness of breath, cough, and fatigue [1] Group 2: Product Information - Shen Ling Bai Zhu San is based on traditional Chinese medicine principles and is used to tonify the spleen and stomach while benefiting lung qi [1]

Core Viewpoint - Tong Ren Tang announced that its subsidiary, Tong Ren Tang Pharmaceutical Factory, received a product license (Class III) from Health Canada for its product Shen Ling Bai Zhu San, which is used to alleviate symptoms of spleen and stomach weakness [1] Group 1 - The product is a powder formulation aimed at addressing specific health issues [1] - The total investment in the product's research and development has reached approximately 2.29 million yuan [1] - The product must still undergo Canadian production quality system certification and other approvals before it can be sold in Canada, indicating uncertainty in the commercialization process [1] Group 2 - The approval of the product is not expected to have a significant impact on the company's recent operating performance [1]